CoChat

Theory and Applications of Covalent Docking in Drug Discovery: Merits and Pitfalls

Open access

The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.

Abstract

he present art of drug discovery and design of new drugs is based on suicidal irreversible inhibitors. Covalent inhibition is the strategy that is used to achieve irreversible inhibition. Irreversible inhibitors interact with their targets in a time-dependent fashion, and the reaction proceeds to completion rather than to equilibrium. Covalent inhibitors possessed some significant advantages over non-covalent inhibitors such as covalent warheads can target rare, non-conserved residue of a particular target protein and thus led to development of highly selective inhibitors, covalent inhibitors can be effective in targeting proteins with shallow binding cleavage which will led to development of novel inhibitors with increased potency than non-covalent inhibitors. Several computational approaches have been developed to simulate covalent interactions; however, this is still a challenging area to explore. Covalent molecular docking has been recently implemented in the computer-aided drug design workflows to describe covalent interactions between inhibitors and biological targets. In this review we highlight: (i) covalent interactions in biomolecular systems; (ii) the mathematical framework of covalent molecular docking; (iii) implementation of covalent docking protocol in drug design workflows; (iv) applications covalent docking: case studies and (v) shortcomings and future perspectives of covalent docking. To the best of our knowledge; this review is the first account that highlights different aspects of covalent docking with its merits and pitfalls. We believe that the method and applications highlighted in this study will help future efforts towards the design of irreversible inhibitors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/molecules20021984

Cites

68 of 68 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Examples of covalent inhibitors including their protein target(s) with active-site nucleophile: (A) aspirin; (B) neratinib; (C) rivastigmine; (D) Crystal structure of EGFR kinase domain in complex with neratinib, showing the covalent bond between the receptor and the ligand [27].
Figure 1 Examples of covalent inhibitors including their protein target(s) with active-site nucleophile: (A) aspirin; (B) neratinib; (C) rivastigmine; (D) Crystal structure of EGFR kinase domain in complex with neratinib, showing the covalent bond between the receptor and the ligand [27].CC BY · PubMed Central
Figure 2 General scheme decribing the workflow of covalent docking in drug discovery.
Figure 2 General scheme decribing the workflow of covalent docking in drug discovery.CC BY · PubMed Central
Figure 3 Implementation of covalent docking within computer-aided drug design approaches. In case of covalent docking target protein explored the interaction between nucleophilic target protein and electrophilic ligand.
Figure 3 Implementation of covalent docking within computer-aided drug design approaches. In case of covalent docking target protein explored the interaction between nucleophilic target protein and electrophilic ligand.CC BY · PubMed Central
Figure 4 Covalent inhibitors, (A,B) bicyclic scaffolds; (C) MG132; (D) MG101; (E) NAC; (F) NMC; (G) GSH; (H,I) dipeptidyl boronic acid proteasome inhibitors.
Figure 4 Covalent inhibitors, (A,B) bicyclic scaffolds; (C) MG132; (D) MG101; (E) NAC; (F) NMC; (G) GSH; (H,I) dipeptidyl boronic acid proteasome inhibitors.CC BY · PubMed Central
Figure 5 Covalent inhibitors: (A) proteasome inhibitor, (R = substituted groups and P = substituted amino acids); (B–D) carbamate derivatives; (E) CP243522.
Figure 5 Covalent inhibitors: (A) proteasome inhibitor, (R = substituted groups and P = substituted amino acids); (B–D) carbamate derivatives; (E) CP243522.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 68 references

Research works printed but not linked: 1

  1. Ding, 2002, Computational manufacturing, Prog. Nat. Sci., 12, 641

Cited by

See all 162

Metadata

Authors
Kumalo, H., Bhakat, S., & Soliman, M.
Affiliations
University of KwaZulu-Natal (ZA)
Corresponding author
Soliman, Mahmoud
Venue
Molecules
Publisher
MDPI AG
Published
2015-01-27
Volume
20
Issue
2
Pages
1984-2000
ISSN
1420-3049 (ISSN-L)
OpenAlex
W2029963983
Cited by
158
References
68
Citations by year
2026: 11 · 2025: 13 · 2024: 10 · 2023: 17 · 2022: 11 · 2021: 17 · 2020: 17 · 2019: 11 · 2018: 13 · 2017: 13 · 2016: 19 · 2015: 5
FWCI
1.76
Type
journal article
Language
en
Open access
Locations
  • Molecules (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Research Foundation
  • Inyuvesi Yakwazulu-Natali
  • Center for High Performance Computing
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
Keywords
covalent docking, covalent inhibitors, irreversible inhibition, computer-aided drug design, covalent interactions, protein-ligand binding, covalent warheads, selective inhibitors
MeSH terms
Humans, Protein Binding, Software, Thermodynamics, Drug Discovery, Molecular Docking Simulation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Theory and Applications of Covalent Docking in Drug Discovery: Merits and Pitfalls. https://app.cochat.ai/papers/10.3390/molecules20021984
The paper
Kumalo, H., Bhakat, S., & Soliman, M. (2015). Theory and Applications of Covalent Docking in Drug Discovery: Merits and Pitfalls. Molecules. https://doi.org/10.3390/molecules20021984

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.